Duane Hassane
Senior Director & Head, Translational Omics, Hematology R&D AstraZeneca
Duane Hassane is currently Head of Translational Omics, Hematology R & D, at AstraZeneca, previously establishing his career as a professor at Weill Cornell Medicine where he focused on cancer progression and biomarker development and subsequently as Vice President of Cardiology & Oncology at Tempus.
Seminars
Tuesday 21st July 2026
Panel Discussion: From Exploratory Signal to Regulatory Confidence: Building the Evidence Base for MRD as an Approved Endpoint
4:30 pm
- Outlining the evidence regulators expect for ctDNA endpoint consideration, including how multiple myeloma secured its first approval
- Identifying gaps between exploratory biomarker use and surrogate endpoint qualification
- Positioning ctDNA endpoints for inclusion in regulatory dialogue and submission packages
Tuesday 21st July 2026
Bridging the Gap: Overcoming Scientific & Operational Barriers to MRD Integration in DLBCL
2:30 pm
- Identifying the key knowledge gaps limiting ctDNA use in DLBCL, including variability in shedding, defining meaningful clearance thresholds, and linking molecular response to clinical decisions
- Confronting standardization challenges across assays and data pipelines to enable regulatory confidence and cross trial comparability
- Tackling logistical constraints and patient experience considerations to ensure ctDNA monitoring is feasible, timely, and truly beneficial in aggressive lymphoma settings
